Clinical Trials · NCT01254123
Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)
- Phase
- Phase 3
- Recruitment status
- Unknown
- Sponsor
- Amsterdam UMC, location VUmc
- Enrollment
- 40
- Start date
- Nov 2009
- Locations
- 1 site, Netherlands
- Primary endpoint
- Safety of GLP-1 receptor agonist Exenatide infusion compared to placebo in patients with an acute myocardial infarction undergoing primary PCI